DNA methylation
|
KLF2 promoter |
Methylation |
HUVEC cells |
Experimental: in vitro
|
(Kumar et al., 2013) |
|
KLF4 promoter |
Methylation |
HAEC cells |
Experimental: in vitro
|
(Jiang et al., 2014) |
|
HECA, EBF1, NOD2, MAP4K4, ZEB1, FYN
|
HECA, EBF1, NOD2: Hypomethylated; MAP4K4, ZEB1, FYN: Hypermethylated |
Human aortic intima and HEK293 cells |
Clinical and experimental: in vitro
|
(Yamada et al., 2014) |
|
TIMP1, ABCA1, ACAT1 promoters |
Altered methylation status |
Peripheral blood |
Clinical |
(Ma et al., 2016) |
|
SMAD7 promoter |
Hypermethylation |
Peripheral blood and atherosclerotic plaques |
Clinical |
(Wei et al., 2018) |
|
5mC, 5-hmC |
Higher levels |
Peripheral blood |
Clinical |
(Jiang et al., 2019) |
Histone modifications
|
HDAC3 |
Deficiency |
Aorta and HUVEC cells |
Experimental: apoE−/− mice and in vitro
|
(Zampetaki et al., 2010) |
|
H3K27Me3 |
Reduction in H3K27Me3 modification |
Perirenal aortic tissue patches |
Clinical |
(Wierda et al., 2015) |
|
H3K9, H3K27 |
Higher histone acetylation and lower histone methylation |
Carotid tissue |
Clinical |
(Greißel et al., 2016) |
miRNA
|
miR-130a, miR-27b, miR-210 |
Higher levels |
Serum and intima tissue |
Clinical |
(Li et al., 2011) |
|
miR-17-5p |
Higher levels |
Plasma |
Clinical |
(Chen et al., 2015a) |
|
miR-143-3p, miR-222-3p |
Lower levels |
Microparticles |
Clinical |
(de Gonzalo-Calvo et al., 2016) |
|
miR-30 |
Lower levels |
Plasma |
Clinical |
(Huang et al., 2016b) |
|
miR-92a |
Higher levels |
Plasma |
Clinical |
(Huang et al., 2017a) |
|
miR-18a-5p, miR-27a-3p, miR-199a-3p, miR-223-3p, miR-652-3p |
Lower levels |
Plasma |
Clinical |
(Vegter et al., 2017) |
|
miR-33a |
Higher levels |
Plasma |
Clinical |
(Kim et al., 2017) |
|
miR-126 |
Lower levels |
Plasma |
Experimental: apoE−/− mice |
(Hao and Fan, 2017) |
|
miR-212 |
Overexpression |
Serum |
Clinical |
(Jeong et al., 2017) |
|
miRNA let-7 |
Higher levels |
Plasma |
Clinical |
(Huang et al., 2017b) |
|
miR-1254 |
Higher levels |
Plasma |
Clinical |
(de Gonzalo-Calvo et al., 2018) |
|
miR-200c |
Overexpression |
Carotid plaques and plasma |
Clinical |
(Magenta et al., 2018) |
|
miR-29c |
Higher levels |
Plasma |
Clinical |
(Huang et al., 2018) |
|
miR-221, miR-222 |
Lower expression levels |
Serum |
Clinical |
(Yilmaz et al., 2018) |
|
miR-638 |
Lower levels |
Serum |
Clinical |
(Luque et al., 2018) |
|
miR-122 |
Higher levels |
Serum |
Clinical |
(Wang and Yu, 2018) |
|
miR-221, miR-222 |
Higher levels in tissue samples and lower levels in whole blood |
Coronary artery atherosclerotic plaques, and internal mammary arteries and whole blood |
Clinical |
(Bildirici et al., 2018) |
|
miR-664a-3p |
Downregulation |
Serum |
Clinical |
(Li et al., 2018b) |
|
miR-155 |
Higher levels |
Serum |
Clinical |
(Qiu and Ma, 2018) |
|
miR-19A, miR-19B, miR-126, miR-155 |
Differential levels |
GEO dataset |
High throughput |
(Mao et al., 2018) |
|
miR-126, miR-143 |
Higher levels |
Plasma |
Clinical |
(Gao et al., 2019) |